Time To Launch Now Skip to main content

Posts

Showing posts with the label GSK's

Brain waste disposal pathway found, signals new revolution in Alzheimer's treatment

 Brain waste disposal pathway found, signals new revolution in Alzheimer's treatment This discovery could completely change the understanding of how the brain stays healthy and why diseases like Alzheimer's develop. Scientists have discovered a new pathway for waste disposal in the human brain, which will help understand brain health and disease. Dr. Onder Albayram 's team at the Medical University of South Carolina used advanced MRI technology to detect fluid flow in the outer layer of the brain. This discovery has proven a direct connection between the brain and the body for waste disposal and could provide a new direction in the treatment of diseases like Alzheimer's. Kathmandu. Scientists have discovered a new pathway for waste disposal in the human brain. This discovery could completely change the understanding of how the brain stays healthy and why diseases like Alzheimer's develop. This study, conducted by researchers at the Medical University of South Ca...

GSK's drug is 60 percent more effective in curing cancer in women

 GSK's drug is 60 percent more effective in curing cancer in women World-renowned pharmaceutical company GSK has announced that the initial results of its new drug ' Mosertatag Rezedacan ', which is used to treat uterine and ovarian cancer , are encouraging. In the first phase of clinical trials, 'Mosertatag Rezedacan' has shown success in platinum-resistant ovarian cancer by 62 percent and in uterine cancer by 67 percent. GSK is preparing to start five large 'Phase-3' clinical trials in 2026 and the drug could change the way cancer is treated, said Hesham Abdullah. World-renowned pharmaceutical company GSK has announced that the initial results of its new drug used to treat uterine and ovarian cancer are very encouraging. The new antibody-drug conjugate (ADC) drug , called mosertatag rezedecan, has shown positive results in a phase 1 clinical trial. The BEHOLD-1 study , presented at the Society of Gynecologic Oncology (SGO) annual meeting in Puerto Rico, ...